DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

Information source: Taro Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Tinea Pedis

Intervention: Butenafine Hydrochloride Cream, 1% (Drug); Lotrimin Ultra® (Drug); Butenafine Vehicle (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Taro Pharmaceuticals USA

Summary

The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra (the reference listed drug) in subjects with interdigital tinea pedis. It will also be determined whether the efficacy of each of the two active treatments is superior to that of the vehicle cream (placebo).

Clinical Details

Official title: A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Therapeutic Cure

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Willing & able to provide & understand written informed consent

- Healthy male or non-pregnant, non-lactating female at least 18 years of age and older

- Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces

or that is predominantly interdigital but may extend to other areas

- Tinea pedis provisionally confirmed at baseline by positive potassium hydroxide

(KOH)wet mount preparation showing segmented fungal hyphae

- Has sum of the clinical signs and symptoms scores of the target lesion of at least 4,

including a minimum score of 2 for erythema & a minimum score of 2 for scaling or pruritus

- Currently in general good health with no clinically significant disease

- Willing and able to understand and comply with study requirements

- Women of childbearing potential must have a negative urine pregnancy test and be

willing to use an acceptable form of birth control during study Exclusion Criteria:

- Females who are pregnant, breastfeeding, planning a pregnancy, or do not agree to use

an acceptable form of birth control during the study

- Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface

- Presence of any other infection of the foot or other disease that might confound

treatment evaluation

- History of dermatophyte infections unresponsive to antifungal drugs

- Known hypersensitivity to Butenafine Hydrochloride or any component of the study

medications

- Use of antipruritics, topical systemic corticosteroid, antibiotic or antifungal

therapy, oral terbinafine or itraconazole, or immunosuppressive medication or radiation therapy more recently than indicated washout period

- Current oral, vaginal, or mucocutaneous candidiasis

- Current bacterial skin infection, secondary cellulitis, lymphangitis, or pyoderma

- Presence of current conditions that require systemic antimicrobial or antifungal

therapy

- Uncontrolled diabetes mellitus, peripheral vascular disease, chronic venous stasis,

or other significant condition

- Current severe onychomycosis

- Any clinically significant condition or situation, other than condition being

studied, that would interfere with the study evaluations or participation

- Use of any investigational drugs or device within 30 days of signing Informed Consent

Form (ICF)

- Current participation in any other clinical study

- Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would

compromise compliance

- Previous participation in this study

- Subjects with past history of tinea pedis with lack of response to antifungal therapy

- Subjects who in Investigator's opinion would be non-compliant

- Employees or direct relatives of an employee of the study center or Investigator

Locations and Contacts

Additional Information

Starting date: January 2012
Last updated: January 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017